Company: SOLA Biosciences
Job title: Co-Founder & Chief Scientific Officer
Dr. Akinori Hishiya is Co-Founder and Chief Scientific Officer of SOLA Biosciences. His most recent invention, Engineered Chaperone Technology, enables the repair of misfolded proteins which can cause devastating neurogenerative diseases such as Huntington and Parkinson’s diseases. He published the platform technology for protein folding of intended proteins in 2017 (Nature Scientific Reports). Prior to SOLA, he worked at Medical College of Georgia, Boston Biomedical Research Institute, and Strategia Pharmaceuticals. He has been a featured speaker at scientific conferences and published in many scientific journals.
Engineered Chaperone Therapeutics: Transformative Therapeutics for Repairing Protein Misfolding of Conformational Diseases 12:30 pm
SOLA is a biotherapeutics company focusing on developing transformative therapies which enable the specific protein folding for disease-causing proteins SOL-01 diminishes aggregation of mutated huntingtin proteins without affecting wild-type huntingtin proteins, and SOL-02 suppresses misfolded alpha-synuclein proteins SOLA’s science team designs the technology for targeted protein folding. SOLA is looking for collaborators and partners to…Read more
day: Day One